Description:

FDA-Approved Phase 3 MDMA/PTSD Research: A $25 million experiment

Description: MAPS' 31 year struggle to begin Phase 3 research into MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), and will review the agreement reached with FDA in July 2017 on the methodological design of our Phase 3 studies. I'll discuss the implementation of Phase 3 and the timeline and steps required to legalize the prescription use of MDMA-assisted psychotherapy, the establishment of psychedelic psychotherapy clinics, and the overall mainstreaming of the legal use of psychedelics into global culture.